Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

6 hours ago

Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy…

USA Rare Earth Reports its First Quarter 2025 Financial Results

6 hours ago

STILLWATER, Okla., May 14, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (“USAR” or the “Company”) today announced…

IREN Reports Q3 FY25 Results

6 hours ago

28% Growth in Profit After Tax Horizon 1 AI Data Center on Track for H2 2025 Pausing Mining Expansion at…

Fossil Group, Inc. Reports First Quarter 2025 Financial Results

6 hours ago

RICHARDSON, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- First quarter worldwide net sales totaled $233 million Gross margin expanded 890…

The Oncology Institute Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Guidance

6 hours ago

CERRITOS, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI) (“TOI” or the “Company”), one of…

zSpace Reports First Quarter 2025 Financial Results

6 hours ago

SAN JOSE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- zSpace (NASDAQ: ZSPC) (“zSpace” or the “Company”), a leader in augmented…

Epsilon Reports First Quarter 2025 Results

6 hours ago

HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today reported first quarter…

Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

6 hours ago

Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions…

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights

6 hours ago

-  Initiated ARTEMIS, the first-ever registrational intravitreal gene therapy trial, in both treatment-experienced and treatment-naive patients with wet AMD -  Presented…

Clearside Biomedical Announces First Quarter 2025 Financial Results and Provides Corporate Update

6 hours ago

- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD…

This website uses cookies.